Want to see ALEC full AI Analyst Report?
ALEC Stock Chart & Stats
$1.51
-$0.01(-0.99%)
At close: 4:00 PM EDT
$1.51
-$0.01(-0.99%)
Day’s Range― - ―
52-Week Range$1.09 - $3.40
Previous CloseN/A
Volume110.63K
Average Volume (3M)768.65K
Market Cap
$167.65M
Enterprise Value$65.80
Total Cash (Recent Filing)$206.51M
Total Debt (Recent Filing)$34.55M
Price to Earnings (P/E)―
Beta2.15
Next Earnings
Nov 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.19
Shares Outstanding111,025,185
10 Day Avg. Volume546,809
30 Day Avg. Volume768,649
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)5.24
Price to Sales (P/S)7.63
P/FCF Ratio-0.87
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$2.83Price Target Upside87.64% Upside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)-0.88
Revenue Forecast (FY)$6.00M
Bulls Say, Bears Say
Bulls Say
Strong Gross MarginAlector reports a TTM gross margin of roughly 82%, indicating favorable product-level economics for its clinical-stage programs. Durable high gross margins imply that if candidates advance, unit costs are controllable and favorable economics can support scale-up and partner negotiations over months ahead.
Established ATM Financing OptionalityThe $125M ATM program gives Alector flexible, programmatic access to equity capital without a single large dilutive event. Over a 2-6 month horizon this optionality reduces urgency to find immediate financing, allowing measured funding of R&D and operations and better timing of capital raises.
Debt Reduction Improved FlexibilityRepaying and terminating the Hercules loan removes a near-term debt obligation and associated covenants/charges. This durable improvement lowers fixed cash outflows, simplifies the balance sheet and modestly expands strategic flexibility when reassessing partnerships and clinical plans over the coming months.
Bears Say
Pipeline Setbacks And Partner LossMultiple clinical failures and GSK’s decision to terminate the collaboration constitute a structural hit to Alector’s development engine. Loss of a major partner removes expected milestone and funding streams, increases the burden to self-fund development or re-license assets, and raises execution risk over quarters.
Sustained Negative Cash Flow / Cash BurnDeeply negative operating and free cash flow (~-$173M TTM) show persistent cash burn that is unlikely to self-correct quickly. This durable cash gap forces reliance on external capital, elevates dilution risk, constrains R&D sequencing, and reduces resilience to further clinical or financing shocks.
Elevated Leverage From Equity ErosionDebt-to-equity increasing to 3.33 reflects significant equity erosion rather than massive new debt, amplifying financial risk. High leverage limits borrowing capacity, raises financing costs, and reduces flexibility to absorb setbacks; this structural fragility persists until equity is meaningfully rebuilt.
Alector News
ALEC FAQ
What was Alector Inc’s price range in the past 12 months?
Alector Inc lowest stock price was $1.09 and its highest was $3.40 in the past 12 months.
What is Alector Inc’s market cap?
Alector Inc’s market cap is $167.65M.
When is Alector Inc’s upcoming earnings report date?
Alector Inc’s upcoming earnings report date is Nov 10, 2026 which is in 99 days.
How were Alector Inc’s earnings last quarter?
Currently, no data Available
Is Alector Inc overvalued?
According to Wall Street analysts Alector Inc’s price is currently Undervalued.
Does Alector Inc pay dividends?
Alector Inc does not currently pay dividends.
What is Alector Inc’s EPS estimate?
Alector Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alector Inc have?
Alector Inc has 111,025,185 shares outstanding.
What happened to Alector Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Alector Inc?
Currently, no hedge funds are holding shares in ALEC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alector Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.83 (87.64% Upside)
$2.83 (87.64% Upside)
Blogger Sentiment
Neutral
ALEC Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 94.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $221.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 3.7%
Last 30 Days ▼ 3.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-14.20%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-41.24%
Trailing 12-Months
Company Description
Alector Inc
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.
ALEC Stock 12 Month Forecast
Average Price Target
$2.83
▲(87.64% Upside)
Technical Analysis
Ownership Overview
7.31% Insiders
11.63% Mutual Funds
0.04% Other Institutional Investors
70.75% Public Companies and
Individual Investors